Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of association between [18F]AV1451 PET and cognition, via direct and/or indirect (mediated by glucose metabolism) pathways, in a cross-sectional sample of amyloid-negative mild cognitive impairment (Aβneg-MCI), amyloid-positive MCI (prodromal AD) and AD dementia patients

Trial Profile

Study of association between [18F]AV1451 PET and cognition, via direct and/or indirect (mediated by glucose metabolism) pathways, in a cross-sectional sample of amyloid-negative mild cognitive impairment (Aβneg-MCI), amyloid-positive MCI (prodromal AD) and AD dementia patients

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2018

At a glance

  • Drugs Flortaucipir-F-18 (Primary) ; Flutemetamol-F-18 (Primary)
  • Indications Alzheimer's disease; Dementia; Mild cognitive impairment
  • Focus Diagnostic use
  • Most Recent Events

    • 03 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top